AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-th... ...

Core Insights - AbbVie reported strong financial results for the fourth quarter and full year of 2025, with a notable increase in net revenues and adjusted diluted EPS guidance for 2026 [1] Financial Performance - Fourth-quarter net revenues reached $16.618 billion, marking a 10.0% increase on a reported basis and 9.5% on an operational basis [1] - Full-year net revenues totaled $61.160 billion, an increase of 8.6% on a reported basis and 8.5% on an operational basis [1] - Fourth-quarter diluted EPS was $1.02 on a GAAP basis, while adjusted diluted EPS was $2.71, reflecting an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense [1] Portfolio Performance - The immunology portfolio generated global net revenues of $30.406 billion for the full year, an increase of 14.0% on a reported basis [1] - The neuroscience portfolio saw a 19.6% increase in global net revenues, totaling $10.767 billion for the full year [1] - The oncology portfolio reported full-year global net revenues of $6.655 billion, a slight increase of 1.5% on a reported basis [1] - The aesthetics portfolio experienced a decline, with full-year global net revenues of $4.860 billion, down 6.1% on a reported basis [1] Recent Developments - AbbVie announced the acquisition of a device manufacturing facility from West Pharmaceutical Services to enhance production capabilities for immunology and neuroscience medicines [1] - An exclusive licensing agreement was established with RemeGen for the development of a novel bispecific antibody, RC148, aimed at treating advanced solid tumors [1] - AbbVie received FDA approval for Epkinly in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma [1] - The company submitted applications for expanded use of Aquipta for migraine treatment and for Rinvoq in treating non-segmental vitiligo [1] 2026 Outlook - AbbVie provided adjusted diluted EPS guidance for 2026 in the range of $14.37 to $14.57, excluding any unfavorable impacts from acquired IPR&D and milestones [1]

Core Insights - GSK reported a strong performance in 2025 with sales growth of 7% at constant exchange rates, reaching over £32 billion, and core operating profit increasing by 11% [3][6] - The company emphasized its focus on specialty medicines, which saw a significant increase of 17%, driven by respiratory, oncology, and HIV segments [5][9] - GSK's guidance for 2026 includes sales growth of 3-5% and core operating profit and EPS growth of 7-9%, alongside a proposed dividend increase of 6% to £0.70 [6][7] Financial Performance - Free cash flow rose to £4.0 billion, with £1.2 billion in Zantac payments expected in 2025, and total shareholder distributions of £4.0 billion through dividends and buybacks [1][3] - Operating margin improved by 110 basis points to 29.9%, driven by better SG&A margins and a shift towards specialty medicines [2][6] - Cash generated from operations was £8.9 billion, supporting investments and a dividend increase of 2p to 66p [3][6] Commercial and Pipeline Developments - Specialty medicines are expected to continue growing at a low double-digit percentage, with HIV products showing mid- to high single-digit growth [7][8] - The company highlighted the importance of upcoming product launches, particularly Extensa and Blenrep, with a focus on execution in 2026 [14][15] - GSK secured five FDA approvals in 2025 and initiated seven new pivotal trials, indicating a robust pipeline and commitment to accelerating development timelines [17][18] Market Trends and Strategic Focus - The company is experiencing broad-based sales growth across all regions, with notable increases in respiratory (18%), oncology (43%), and HIV (11%) segments [9][12][11] - GSK's management is prioritizing business development and simplifying operations while increasing the use of technology such as AI [4][19] - The planned acquisition of RAPT Therapeutics aims to advance the development of Ozuriquibat, a long-acting anti-IgE monoclonal antibody [19]

Novo Nordisk A/S shares plunged after the company shocked investors by forecasting a steep decline in sales, evidence of an intensifying price war in obesity drugs.Sales will fall by as much as 13% this year, the company said Tuesday. Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government's push to cut prices, will contribute to the decline. The shares fell as much as 20% in early Copenhagen trading, the biggest intraday decline since July, more than wiping out t ...

Group 1 - Eli Lilly reported higher fourth-quarter profit driven by increased demand for its GLP-1 weight-loss drugs [1]

Lilly says Mounjaro and Zepbound sales more than doubled as stock rallies - MarketWatch# Lilly says Mounjaro and Zepbound sales more than doubled as stock rallies## The drugmaker also detailed strong growth for 2026Last Updated: Feb. 4, 2026 at 7:32 a.m. ETFirst Published: Feb. 4, 2026 at 7:21 a.m. ETShareResize--- Listen(3 min)Eli Lilly said its fourth-quarter sales grew by 43% to $19.3 billion, surpassing the FactSet estimate of $17.9 billion. Photo: Getty ImagesEli Lilly's stock soared 7% in premarket tr ...

It is Wednesday, the fourth. Good morning, everybody, on today's agenda. UBS reports upbeat but wealth management raises questions.Sometimes they go shopping in the U.S. and trans-Atlantic software angst builds. European futures are currently flat, but that rotation trade in the US. And of course, the software selloff remains in focus.Another massive day for European earnings. NASDAQ 100 futures pointing lower. In fact, that was to close down 1.4%.The futures are flat, but this is what happened in terms of ...

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2][5] - Core operating profit grew by 11%, and EPS was up by 12% [2][29] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend increase of 2p to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and oncology [5][6] - Respiratory immunology and inflammation sales increased by 18%, driven by Benlysta and Nucala [5][6] - Oncology sales surged by 43%, with Jemperli sales up by 89% [6][7] - Vaccine sales were GBP 9.2 billion, up 2%, with Shingrix and Bexsero driving growth [15][16] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [6] - The U.S. market for HIV treatment grew by 14%, with long-acting injectables contributing significantly to sales [10][11] - Ex-U.S. markets represented 69% of Bexsero's global sales, indicating strong international demand [16] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing product launches and accelerating key assets in late-stage portfolios [3][4] - A focus on simplifying operations and leveraging AI and technology to enhance efficiency [4] - The strategy includes a commitment to long-acting treatments in HIV, with plans for Q6M treatment regimens [12][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued profitable growth for 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32][34] - The company is navigating challenges such as currency headwinds and pricing pressures but remains optimistic about its pipeline and market position [34][36] - Management emphasized the importance of evolving the company to be more product-centric and agile in capitalizing on opportunities [37] Other Important Information - The company secured 5 FDA approvals and initiated 7 new pivotal trials in 2025 [18] - The acquisition of RAPT Therapeutics for Ozuriquimab, a long-acting anti-IgE monoclonal for food allergies, is expected to close soon [27] - The company is on track to deliver significant data readouts and pivotal starts in 2026, supporting growth in specialty medicines [28] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of multiple products targeting different patient populations within COPD and asthma, emphasizing a strategic approach to avoid overlap [40][43] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that the Q6M treatment regimen is on track for phase IIb this year, with significant market potential for long-acting injectables in HIV treatment [49][50] Question: Can you update us on the launch trajectory for Blenrep? - Initial feedback indicated a slow but positive ramp-up for Blenrep, with a focus on educating eye care professionals and ensuring a positive experience for patients [59][63]

Core Insights - CC Pharma, the European pharmaceutical distribution business of Tilray Brands, has been recognized as a TOP 100 Innovator in Germany, highlighting its innovative strength and contributions to the pharmaceutical sector [1][3]. Company Overview - CC Pharma operates a nationwide distribution network serving over 13,000 pharmacies in Germany, providing access to a wide range of prescription and over-the-counter medicines [2]. - The company is also a key player in the distribution of medical cannabis in Germany, utilizing its established infrastructure and regulatory expertise to enhance patient access in a regulated market [2]. Recognition and Awards - The TOP 100 Innovator Award has been recognizing companies for over 25 years based on their innovative management, forward-looking strategies, and sustainable competitiveness [3]. - CC Pharma's selection as a TOP 100 Innovator reflects its disciplined innovation strategy and commitment to operational excellence in a highly regulated market [4]. Leadership Statements - Rajnish Ohri, President of International at Tilray Brands, emphasized that this recognition underscores CC Pharma's role as a reliable partner in Germany's pharmaceutical ecosystem, focusing on building resilient systems and delivering value [4]. - Mathias Bossen, Managing Director of CC Pharma, expressed pride in the award, highlighting the team's focus on continuous improvement and digitalization, positioning the company as a trusted partner in the pharmaceutical value chain [4]. Market Position - CC Pharma's recognition as a TOP 100 Innovator enhances its reputation as an attractive employer and a significant contributor to Germany's healthcare supply chain [4].

Core Viewpoint - Tenax Therapeutics, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing novel cardiopulmonary therapies [1]. Company Overview - Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company specializing in cardiopulmonary therapies [3]. - The company holds global rights to develop and commercialize levosimendan, targeting PH-HFpEF, the most common form of pulmonary hypertension, for which no product has been approved to date [3]. - Tenax Therapeutics is publicly traded on The Nasdaq Stock Market under the symbol "TENX" [3]. Event Details - The fireside chat will feature Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer [2]. - The event is scheduled for February 11, 2026, at 12:30 p.m. ET [2]. - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2].